



# Register of declared interests – permanent group

## Scottish Health Technologies Group (SHTG) Council 2024

Name	Date of declaration	Role in Group	Personal Financial	Personal non-financial	Non-personal financial	Non-personal non-financial	Other
Neil Smart	14/03/2024	Chair	<b>Name of Company/Org:</b> Interim Devices Working Group advising MHRA <b>Nature of Interest:</b> Committee Member	None	None	None	None
Ed Clifton	13/03/2024	Member	None	None	None	None	None
Claire Fernie	07/04/2024	Member	None	<b>Name of Company/Org:</b> Ileostomy & Internal Pouch Association (IA) <b>Nature of Interest:</b> Honorary member  <b>Name of Company/Org:</b> Ileostomy &	None	None	None

Name	Date of declaration	Role in Group	Personal Financial	Personal non-financial	Non-personal financial	Non-personal non-financial	Other
------	---------------------	---------------	--------------------	------------------------	------------------------	----------------------------	-------

				<p>Internal Pouch Association (IA)  <b>Nature of Interest:</b>  Local executive chair  <b>Date interest ceased:</b> November 2021</p> <p><b>Name of Company/Org:</b>  NHS Fife ADTC  <b>Nature of Interest:</b>  Lay member  <b>Date interest ceased:</b> December 2023</p> <p><b>Name of Company/Org:</b>  University of St Andrews, Medical School/NHS Fife  <b>Nature of Interest:</b>  Fife Community Advisor Council Member</p> <p><b>Name of Company/Org:</b>  Scottish Government  <b>Nature of Interest:</b>  National Medical Devices Committee Lay Member</p>			
Kate Dion							
Colin Marsland	14/12/2022	Member	None	None	None	None	None

Rodolfo Hernandez	15/04/2024	Member	None	None	None	None	None
Karen Facey	13/04/2024	Member	<p><b>Name of Company/Org:</b> Medical Device Co</p> <p><b>Name of Company/Org:</b> Edwards Life Sciences</p> <p><b>Nature of Interest:</b> Fee to deliver lecture on RWD</p> <p><b>Date interest ceased:</b> February 2023</p> <p><b>Investors:</b></p> <p><b>BGF</b> - Fee to act as member of Life Sciences Advisory Group (Dec 2023)</p> <p><b>Pharmaceutical Cos and Consultancies:</b></p> <p><b>Novartis</b> - Fees for advice on clinical development of a medicine for rare kidney disease, RWE and health service policy issues (Ongoing)</p> <p><b>Sanofi</b> - Fees for participation in Global Think Tank (Ongoing)</p> <p><b>FIPRA</b> – Fees for facilitation of RWE4 Decisions learning network (Ongoing)</p> <p><b>Costello Medical</b> - Fees for participation in ad board about inclusion of medical opinion (Dec 2023)</p> <p><b>Pfizer</b> - Webinar on gene therapies (Sept 2023)</p> <p><b>Roche</b> – Lectures on RWE (Sept 2023)</p> <p><b>Alira Health</b> - Lecture on patient involvement in HTA to industry (June 2023)</p> <p><b>EUPATI</b>- Training on patient involvement in HTA to industry (June 2023)</p>	<p><b>Name of Company/Org:</b> Waldenstroms Macroglobunaemia</p> <p><b>Nature of Interest:</b> Member of registries research committee</p> <p><b>Date:</b> Ongoing</p>			

			<p><b>Dolon</b> - Ad board on rare diseases in older people (April 2023)</p> <p><b>Inbeeo</b> - Ad board re EU HTA regulation for OMPs (Feb 2023)</p> <p><b>Biogen</b> - Webinar re RWD (April 2022)</p> <p><b>Novartis</b> - Input to European Think Tank (Dec 2021)</p> <p><b>BMS</b> - Patient training (Dec 2021)</p> <p><b>Merck</b> - RWD webinar (Dec 2021)</p> <p><b>Decisive Consulting, Alira, P4Access, Medicus Economics, Curta, AXS, Atheneum, Ipsos, Biointelect, Xcenda, MAT</b> - Fee for 1-hour interviews re development of a medicine (Over the 3 years)</p> <p><b>Public Bodies:</b></p> <p><b>Health Technology Wales</b> - Salary for payment as member of PPI Standing Group (Ongoing)</p> <p><b>Utrecht University</b> - Salary for half-day work in SUSTAIN HTA project (Ongoing)</p> <p><b>Ministry of National Guard Health Affairs-</b> Fee for presentations on OBMEA for medicines (Feb 2024)</p> <p><b>World Health Organisation Europe</b> - Fee for facilitation of Novel Medicines Platform (Dec 2023)</p> <p><b>National Institute for Health and Care Excellence</b> - Fee for Scientific Advice of a medicine (Sept 2023)</p> <p>Review of new methods vs IMPACT HTA framework (March 2022)</p> <p><b>European commission</b> - Fees for review of imi grants and project outputs (Oct 2022)</p>				
--	--	--	---	--	--	--	--

			<p><b>CADTH</b> - Fee for input on scanning report re OBMEA and facilitation of RWD workshop (March &amp; Dec 2022)</p> <p><b>National Institute for Health and Disability Insurance, Belgium</b> - Fees for facilitation of workshops re RWE (Sept 2021)</p>				
Katie Hislop	13/03/2024	Member	None	None	None	None	None
Mark Cook	26/09/2022	Member	<p><b>Name of Company/Org:</b> Medtronic, Pfizer, Lilly, Novo Nordisc</p> <p><b>Nature of Interest:</b> Shares in ISA investments</p> <p><b>Name of Company/Org:</b> Scottish Brain Science</p> <p><b>Nature of Interest:</b> Shares &amp; Salary</p> <p><b>Name of Company/Org:</b> ABHI</p> <p><b>Nature of Interest:</b> Salary</p>	<p><b>Name of Company/Org:</b> Chair ABHI</p> <p>Scotland, Chair Life Science Scotland, Chair Scottish Public Pensions Authority Teachers Scheme</p>	None	None	None
Fatim Lakha	13/03/2024	Member	None	None	None	None	<p><b>Name of Company/Org:</b> ANIA</p> <p><b>Nature of Interest:</b> PHS are an AHIA partner and I am one of the leads within PHS providing that PHS input</p>
Gordon James	26/03/2024	Member	None	<p><b>Name of Company/Org:</b> INNOSCOT</p> <p><b>Nature of Interest:</b> Board Member</p>	None	None	None
Julie Calvert	13/03/2024	Member	None	None	None	None	None